MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.antiviral.2026.106439

Медицинская библиотека · Antiviral research · 2026

Bemnifosbuvir and remdesivir inhibit tick-borne encephalitis virus infection in complementary in vitro and ex vivo disease models.

Leoni Simone, Schultz-Pernice Isabel, Krátka Zuzana, Freiholz Lucie, Fahmi Amal, David Teodora, Golomingi Antoinette, Blank Fabian, Beránková Michaela, Dejmek Milan, Grandgirard Denis, Dijkman Ronald, Růžek Daniel, Eyer Luděk, Alves Marco P, Leib Stephen L

СтатьяПеревод в очереди

Аннотация

The geographical distribution and incidence of tick-borne encephalitis (TBE) have steeply increased over the past decades, raising to represent a major health concern in Asia and Europe. Symptoms of TBE, caused by infections with tick-borne encephalitis virus (TBEV), range from mild flu-like symptoms to severe neurological disease, often accompanied by long-term sequelae persisting for several years following pathogen encounter. While effective vaccines against TBEV are available, no antiviral drugs are currently approved and therapeutic options for patients suffering from TBE are limited to supportive measures. Compounds able to disrupt viral nucleic acid synthesis bear the potential of effectively limiting viral replication and spread. Seeking to fill the therapeutic gap, we evaluated the efficacy of a panel of approved and investigational antiviral compounds in containing TBEV infection. Combining several cell lines, human neural organoids, and organotypic rat brain slice cultures, we found that the nucleotide analogs remdesivir and bemnifosbuvir efficiently limit viral replication. Through infectious virus quantification, immunofluorescence analysis, and flow cytometry, we report significant, dose-dependent reduction of viral loads across all models used with inhibition observed at low doses for both drugs. Notably, while we observed bemnifosbuvir to be well tolerated, we report important cytotoxicity of remdesivir when applied to human neural organoids. Our findings identify bemnifosbuvir and remdesivir as novel treatment strategies for TBE, providing an accessible and timely response to a clinical challenge of pressing concern.

Для цитирования: Leoni Simone, Schultz-Pernice Isabel, Krátka Zuzana, Freiholz Lucie, Fahmi Amal, David Teodora, Golomingi Antoinette, Blank Fabian, Beránková Michaela, Dejmek Milan, Grandgirard Denis, Dijkman Ronald, Růžek Daniel, Eyer Luděk, Alves Marco P, Leib Stephen L. Bemnifosbuvir and remdesivir inhibit tick-borne encephalitis virus infection in complementary in vitro and ex vivo disease models.. Antiviral research. 2026. DOI: 10.1016/j.antiviral.2026.106439.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.